CAPR — CAPRICOR THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1133869 ·
Last close
$8.41
Market Cap
$488.98M
52W High
$40.37
52W Low
$2.96
ADV30
3,566,837
Next earnings
2026-11-10
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -44,682,736 -42,656,101 330,370,421 44,279,993 120,605,812
Jun 2026 0 — -42,945,620 -40,733,654 368,735,835 20,935,187 122,516,945
Mar 2026 0 — -36,772,853 -33,941,345 326,283,517 105,421,484 47,580,884
Dec 2025 0 — -29,156,008 -30,170,914 355,949,294 287,847,312 50,157,149

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-119,994,953
Investing CF
$-100,409,531
Financing CF
$246,131,709
CapEx
$-26,291,272
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.64
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-422,209,585
Inventory
—
Receivables
$0
ST Investments
$153,300,986
EBIT TTM
$-147,411,708
Pretax Income TTM
$-147,498,814
Interest Exp TTM
—
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -108,142,130 -105,043,946 355,949,294 50,157,149 305,792,145 -69,811,261
Dec 2024 22,270,465 -42,563,242 -40,467,186 170,481,086 25,018,750 145,462,336 -39,995,742
Dec 2023 25,178,066 -24,077,859 -22,287,542 58,734,327 36,132,860 22,601,467 -25,596,545
Dec 2022 2,551,469 -29,697,383 -29,019,532 50,094,910 38,308,816 11,786,094 4,916,637

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-129,416,560
OpCashFlow TTM
—
Assets (Latest)
$368,735,835
Forward EPS
$-1.31

Max Pain — expiry 2026-11-27

max pain strike: $8.50 · spot: $8.03 · call oi: 5,952 · put oi: 10,197
Expected Move to 2026-11-27: ±$8.53 (106.16%) — implied range $-0.50 – $16.55 · ATM straddle on $8.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GYRE GYRE THERAPEUTICS, INC. $488.23M $4.56 —
MNPR Monopar Therapeutics $481.56M $71.06 —
BLSM BlossomHill Therapeutics, Inc. $480.91M $15.13 —
IMMP IMMUTEP Ltd $480.43M $3.26 —
NGNE Neurogene Inc. $478.19M $23.10 —

News headlines (Yahoo Finance, 1h cache)

CAPR Stock Has Retail’s Attention After SLS Rally — Here Are 2 Drugs With Better FDA Approval Odds This Month
2026-11-18 07:51 · Yahoo
‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel
2026-11-17 20:53 · Yahoo
FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
2026-11-16 10:09 · Yahoo
SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
2026-11-16 01:49 · Yahoo
CAPR Stock Rallies: Investors Scrutinize Labeling Hints Before FDA Decision On Cell Therapy This Month
2026-11-11 17:42 · Yahoo
Capricor Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
Capricor Therapeutics Inc (CAPR) (Q3 2026) Earnings Call Highlights: Deramiocel Nears PDUFA ...
2026-11-11 07:08 · Yahoo
Capricor (CAPR) Q3 2026 Earnings Call Transcript
2026-11-11 03:34 · Yahoo
Capricor Therapeutics Q3 Earnings Call Highlights
2026-11-11 00:14 · Yahoo
CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review
2026-11-10 23:56 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.